Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Why April 1st?
View:
Post by Gbathat on May 19, 2021 9:35pm

Why April 1st?

I'm still stuck on the April 1st date for accreditation of serology assay.  It is too coincidental that it just happened to fall one day after the reporting period.  Question is, why would they not want to disclose this awesome development?

Choose the best answer

a. They hate us, Elliot is just rolling in our dollars, and it's all a big lie (farmerjane's answer)
b. Licensing discussions with big pharma partner and a desire to not front run associated PRs by big pharma
c. BCNI just wants to have everything all set before the PRs so they don't get overwhelmed with test kit enquiries prior to having scaled up manufacturing/distribution?
d. other,  ___________


My hope is it's B.  C would be okay too.
Comment by Thenorth1990 on May 20, 2021 4:19am
we will take a back up for June 4 in case Aducanumab gets rejected , for which the probability is really high . So there is a a good chance we drop another 60% and then they might announce . It will awesome if biogen is given a green light
Comment by DavidKingCanada on May 20, 2021 10:52am
The only reason PMN.to is staying above 0.17 is because of the new Investors and Board of Directors. Even if Aducanumab is rejected, I don't see the price dropping 60%. If it does, I'm buying all the Stocks available!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities